Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wake Forest study could lead to new cholesterol drugs
Researchers from Wake Forest University school of medicine and colleagues conducted a study that used gene-targeting in mice to simulate Tangier disease, a rare human disease. People with
Researchers from Wake Forest University school of medicine and colleagues conducted a study that used gene-targeting in mice to simulate Tangier disease, a rare human disease. People with
A study co-authored by Oregon Health & Science University researcher Dr David Grandy found a link between dopamine supersensitivity and increased levels of a dopamine receptor with a
The patent is the company’s 13th US patent and its second patent issued for the treatment of stroke. “Presently there are limited treatment options for acute stroke victims,”
Researchers at Yale School of Medicine and the VA Connecticut Healthcare System in West Haven, Connecticut discovered the protein, which regulates both heart contraction and blood pressure. Renalase
Fosamax Plus D (alendronate sodium/cholecalciferol), the only bisphosphonate with a weekly dose of vitamin D added, contains 70mg Fosamax (alendronate sodium) and 2800 IU vitamin D3, representing seven
An interference is a proceeding brought before the Patent Office when two patent applications containing allowed claims, or an issued patent and an allowed patent application, claim essentially
Celgene’s lead immunomodulatory drug (IMiD), Revlimid (lenalidomide), has received both orphan drug status and fast track designation from the FDA and orphan drug status from the EMEA for
Capridine-Beta is a novel nitroacridine derivative which has shown specific activity against prostate cancer and which, as preclinical toxicology studies have indicated, may be less myelosupressive than commonly
The two companies have initiated enrolment in the international randomized controlled phase III study, named CHOPIN, to evaluate BAL5788 (ceftobiprole) in hospital-acquired pneumonia including ventilator-associated pneumonia. “We are
The study, named EXOTIC-EF, involved intravenous dosing of 400mg of oxypurinol on a one-time basis with measurement of left-ventricle ejection fraction (LVEF) the endpoint. The study was open-label